JMJD4

Across TCGA pan-cancer cohorts, JMJD4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated JMJD4 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher JMJD4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated JMJD4 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

LSCC, CCRCC, and UCEC are the cancer types where JMJD4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	1.000	0.784	.007	31	view →
CCRCC	DFS	Median	III,IV	1.000	0.730	.020	5	view →
UCEC	DFS	Median	All	0.963	0.822	.048	4	view →
GBM	DFS	Median	All	0.514	0.281	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

JMJD4–LSCC (DFS)

Open the LSCC breakdown →